in Treating Cardiovascular Diseases: A Review on Its Pharmacological and Clinical Applications

Overview

Journal Front Pharmacol

Date 2019 Jul 25

PMID 31338034

Citations 105

Authors

Jie Ren

Li Fu

Shivraj Hariram Nile

Jun Zhang

Guoyin Kai

Affiliations

Soon will be listed here.

Abstract

Bioactive chemical constitutes from the root of classified in two major groups, viz., liposoluble tanshinones and water-soluble phenolics. Tanshinone IIA is a major lipid-soluble compound having promising health benefits. The and studies showed that the tanshinone IIA and salvianolate have a wide range of cardiovascular and other pharmacological effects, including antioxidative, anti-inflammatory, endothelial protective, myocardial protective, anticoagulation, vasodilation, and anti-atherosclerosis, as well as significantly help to reduce proliferation and migration of vascular smooth muscle cells. In addition, some of the clinical studies reported that the preparations in combination with Western medicine were more effective for treatment of various cardiovascular diseases including angina pectoris, myocardial infarction, hypertension, hyperlipidemia, and pulmonary heart diseases. In this review, we demonstrated the potential applications of , including pharmacological effects of salvianolate, tanshinone IIA, and its water-soluble derivative, like sodium tanshinone IIA sulfonate. Moreover, we also provided details about the clinical applications of preparations in controlling the cardiovascular diseases.

Citing Articles

Progress of tanshinone IIA against respiratory diseases: therapeutic targets and potential mechanisms.

Ding Z, Deng Y, Luo H, Liu C, Yang M, Xue H Front Pharmacol. 2025; 16:1505672.

PMID: 40066338 PMC: 11891354. DOI: 10.3389/fphar.2025.1505672.

Traditional Chinese medicine for chronic atrophic gastritis: Efficacy, mechanisms and targets.

Wang L, Lian Y, Dong J, Liu M, Liu H, Cao Z World J Gastroenterol. 2025; 31(9):102053.

PMID: 40061592 PMC: 11886037. DOI: 10.3748/wjg.v31.i9.102053.

Natural product virtual-interact-phenotypic target characterization: A novel approach demonstrated with Salvia miltiorrhiza extract.

Xu R, Yu H, Wang Y, Li B, Chen Y, Liu X J Pharm Anal. 2025; 15(2):101101.

PMID: 39957901 PMC: 11830376. DOI: 10.1016/j.jpha.2024.101101.

Protective Effect of Carbon Dots Derived from Pretreatment in Acute Myocardial Infarction in Rats.

Dong L, Li M, Cao T, Zhao Y, Wang S, Zou P Nanomaterials (Basel). 2025; 15(3).

PMID: 39940217 PMC: 11821062. DOI: 10.3390/nano15030242.

Pharmacological Mechanisms of Cryptotanshinone: Recent Advances in Cardiovascular, Cancer, and Neurological Disease Applications.

Zheng Z, Ke L, Ye S, Shi P, Yao H Drug Des Devel Ther. 2024; 18:6031-6060.

PMID: 39703195 PMC: 11658958. DOI: 10.2147/DDDT.S494555.

References

Paolocci N, Biondi R, Bettini M, Lee C, Berlowitz C, Rossi R . Oxygen radical-mediated reduction in basal and agonist-evoked NO release in isolated rat heart. J Mol Cell Cardiol. 2001; 33(4):671-9. DOI: 10.1006/jmcc.2000.1334. View

Lu T, Ding Y, Lin S, Lee W, Tai H . Plasma levels of asymmetrical dimethylarginine and adverse cardiovascular events after percutaneous coronary intervention. Eur Heart J. 2003; 24(21):1912-9. DOI: 10.1016/j.ehj.2003.08.013. View

Xia Z, Gu J, Ansley D, Xia F, Yu J . Antioxidant therapy with Salvia miltiorrhiza decreases plasma endothelin-1 and thromboxane B2 after cardiopulmonary bypass in patients with congenital heart disease. J Thorac Cardiovasc Surg. 2003; 126(5):1404-10. DOI: 10.1016/s0022-5223(03)00970-x. View

Tsang A, Hausenloy D, Mocanu M, Yellon D . Postconditioning: a form of "modified reperfusion" protects the myocardium by activating the phosphatidylinositol 3-kinase-Akt pathway. Circ Res. 2004; 95(3):230-2. DOI: 10.1161/01.RES.0000138303.76488.fe. View

Bopassa J, Ferrera R, Gateau-Roesch O, Couture-Lepetit E, Ovize M . PI 3-kinase regulates the mitochondrial transition pore in controlled reperfusion and postconditioning. Cardiovasc Res. 2005; 69(1):178-85. DOI: 10.1016/j.cardiores.2005.07.014. View

Opie L, Commerford P, Gersh B, Pfeffer M . Controversies in ventricular remodelling. Lancet. 2006; 367(9507):356-67. DOI: 10.1016/S0140-6736(06)68074-4. View

Chen K, Shi D, Xu H, Lu S, Li T, Ke Y . XS0601 reduces the incidence of restenosis: a prospective study of 335 patients undergoing percutaneous coronary intervention in China. Chin Med J (Engl). 2006; 119(1):6-13. View

Zhou L, Chow M, Zuo Z . Improved quality control method for Danshen products--consideration of both hydrophilic and lipophilic active components. J Pharm Biomed Anal. 2006; 41(3):744-50. DOI: 10.1016/j.jpba.2005.12.032. View

Chow C, Cardona M, Raju P, Iyengar S, Sukumar A, Raju R . Cardiovascular disease and risk factors among 345 adults in rural India--the Andhra Pradesh Rural Health Initiative. Int J Cardiol. 2006; 116(2):180-5. DOI: 10.1016/j.ijcard.2006.03.043. View

10.

Lam F, Yeung J, Kwan Y, Chan K, Or P . Salvianolic acid B, an aqueous component of danshen (Salvia miltiorrhiza), relaxes rat coronary artery by inhibition of calcium channels. Eur J Pharmacol. 2006; 553(1-3):240-5. DOI: 10.1016/j.ejphar.2006.09.030. View

11.

Krishnan E, Kwoh C, Schumacher H, Kuller L . Hyperuricemia and incidence of hypertension among men without metabolic syndrome. Hypertension. 2006; 49(2):298-303. DOI: 10.1161/01.HYP.0000254480.64564.b6. View

12.

Zhang S, Cheng Z, Lin Y, Qin J, Cheng Y, Liu S . [Effection of compositie salviae dropping pill on hyperlipemia patients with phlegm and blood stasis syndrome]. Zhongguo Zhong Yao Za Zhi. 2007; 32(5):440-3. View

13.

Liu M, Li Y, Zhang F, Yang L, Chou G, Wang Z . Chromatographic fingerprinting analysis of Danshen root (Salvia miltiorrhiza Radix et Rhizoma) and its preparations using high performance liquid chromatography with diode array detection and electrospray mass spectrometry (HPLC-DAD-ESI/MS). J Sep Sci. 2007; 30(14):2256-67. DOI: 10.1002/jssc.200700149. View

14.

Han M, McLaughlin V, Criner G, Martinez F . Pulmonary diseases and the heart. Circulation. 2007; 116(25):2992-3005. DOI: 10.1161/CIRCULATIONAHA.106.685206. View

15.

Shujaat A, Minkin R, Eden E . Pulmonary hypertension and chronic cor pulmonale in COPD. Int J Chron Obstruct Pulmon Dis. 2008; 2(3):273-82. PMC: 2695205. View

16.

Sanz J, Fayad Z . Imaging of atherosclerotic cardiovascular disease. Nature. 2008; 451(7181):953-7. DOI: 10.1038/nature06803. View

17.

Laaksonen D, Niskanen L, Nyyssonen K, Lakka T, Laukkanen J, Salonen J . Dyslipidaemia as a predictor of hypertension in middle-aged men. Eur Heart J. 2008; 29(20):2561-8. PMC: 2721716. DOI: 10.1093/eurheartj/ehn061. View

18.

Wu T, Ni J, Wu J . Danshen (Chinese medicinal herb) preparations for acute myocardial infarction. Cochrane Database Syst Rev. 2008; (2):CD004465. PMC: 8406986. DOI: 10.1002/14651858.CD004465.pub2. View

19.

Panda V, Naik S . Cardioprotective activity of Ginkgo biloba Phytosomes in isoproterenol-induced myocardial necrosis in rats: a biochemical and histoarchitectural evaluation. Exp Toxicol Pathol. 2008; 60(4-5):397-404. DOI: 10.1016/j.etp.2008.03.010. View

20.

Lu Z, Kou W, Du B, Wu Y, Zhao S, Brusco O . Effect of Xuezhikang, an extract from red yeast Chinese rice, on coronary events in a Chinese population with previous myocardial infarction. Am J Cardiol. 2008; 101(12):1689-93. DOI: 10.1016/j.amjcard.2008.02.056. View